GlassScriptPhysician profile
Danuta K Hoyer
NPI 1477664506
$1,533.56
in general payments reported to CMS, 2019-2025
20 companies · $17.71 in 2025
The $17.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $394 · 2021: $358 · 2022: $184 · 2023: $44.05 · 2024: $209 · 2025: $17.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $348.56 | 2019-2021 | |
| Amgen INC. | $176.85 | 2019-2024 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.94 | 2019-2024 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $160.44 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.71 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $120.77 | 2021 | |
| Allergan, INC. | $73.45 | 2019-2020 | |
| Pfizer INC. | $68.32 | 2019-2020 | |
| Abbvie INC. | $49.94 | 2019-2023 | |
| Novo Nordisk INC | $48.86 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Therapeuticsmd, INC. | $36.62 | 2019 | |
| Neurocrine Biosciences, INC. | $23.43 | 2022 | |
| Alfasigma USA, INC. | $22.43 | 2020 | |
| Azurity Pharmaceuticals, INC. | $21.86 | 2022 | |
| Exact Sciences Corporation | $17.71 | 2025 | The Cologuard Plus Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $17.30 | 2020 | |
| Radius Health, INC. | $16.22 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.84 | 2019 | |
| Sumitomo Pharma America, INC. | $13.59 | 2024 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danuta Hoyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.